US2011263522A1PendingUtilityA1
Antitumour compositions containing taxane derivatives
Est. expiryNov 10, 2012(expired)· nominal 20-yr term from priority
Inventors:Marie-Christine Bissery
A61P 35/02A61P 35/00A61K 31/66A61K 31/675A61K 31/335A61K 31/505A61K 31/337A61K 38/20C12Y 305/01001A61K 45/06A61K 31/7072A61K 38/21A61K 38/50A61K 31/7048A61K 31/4745C07D 305/14A61K 31/525A61K 33/243
61
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Antitumor combinations comprising a taxane and at least one antibiotic for treating neoplastic diseases are described.
Claims
exact text as granted — not AI-modified1 - 14 . (canceled)
15 . A method of treating a cancer in a human patient comprising administering an effective amount of a combination of docetaxel, doxorubicin, and cyclophosphamide to the patient, wherein the combination has greater anticancer activity in the human patient than the optimum dose of docetaxel alone, the optimum dose of doxorubicin alone, or the optimum dose of cyclophosphamide alone against said cancer in a human patient.
16 . The method of claim 15 , wherein the docetaxel, doxorubicin, and cyclophosphamide are each present in a separate pharmaceutically acceptable composition and the compositions are administered simultaneously.
17 . The method of claim 15 , wherein the docetaxel, doxorubicin, and cyclophosphamide are each present in a separate pharmaceutically acceptable composition and the compositions are administered sequentially.
18 . The method of claim 15 , wherein the cancer is lung cancer.
19 . The method of claim 15 , wherein the cancer is breast cancer.
20 . The method of claim 15 , wherein the cancer is ovarian cancer.
21 . The method of claim 15 , wherein the cancer is adenocarcinoma.
22 . The method of claim 15 , wherein the cancer is melanoma.
23 . The method of claim 15 , wherein the cancer is leukemia.
24 . The method of claim 15 , wherein the docetaxel, doxorubicin, and cyclophosphamide are each administered parenterally or intraperitoneally.
25 . The method of claim 24 , wherein the docetaxel, doxorubicin, and cyclophosphamide are each administered intravenously.
26 . A method of treating a cancer in a human patient comprising administering an effective amount of a combination of docetaxel, doxorubicin, and cyclophosphamide to the patient, wherein the combination has greater anticancer activity in the human patient than the optimum dose of docetaxel alone, the optimum dose of doxorubicin alone, and the optimum dose of cyclophosphamide alone against said cancer in a human patient.
27 . The method of claim 26 , wherein the docetaxel, doxorubicin, and cyclophosphamide are each present in a separate pharmaceutically acceptable composition and the compositions are administered simultaneously.
28 . The method of claim 26 , wherein the docetaxel, doxorubicin, and cyclophosphamide are each present in a separate pharmaceutically acceptable composition and the compositions are administered sequentially.
29 . The method of claim 26 , wherein the cancer is lung cancer.
30 . The method of claim 26 , wherein the cancer is breast cancer.
31 . The method of claim 26 , wherein the cancer is ovarian cancer.
32 . The method of claim 26 , wherein the cancer is adenocarcinoma.
33 . The method of claim 26 , wherein the cancer is melanoma.
34 . The method of claim 26 , wherein the cancer is leukemia.
35 . The method of claim 26 , wherein the docetaxel, doxorubicin, and cyclophosphamide are each administered parenterally or intraperitoneally.
36 . The method of claim 35 , wherein the docetaxel, doxorubicin, and cyclophosphamide are each administered intravenously.
37 . A method of treating a cancer in a human patient comprising administering an effective amount of a combination of docetaxel, doxorubicin, and cyclophosphamide to the patient, wherein the combination has greater anticancer activity in the human patient than the maximum tolerated dose of docetaxel alone, the maximum tolerated dose of doxorubicin alone, or the maximum tolerated dose of cyclophosphamide alone against said cancer in a human patient.
38 . The method of claim 37 , wherein the docetaxel, doxorubicin, and cyclophosphamide are each present in a separate pharmaceutically acceptable composition and the compositions are administered simultaneously.
39 . The method of claim 37 , wherein the docetaxel, doxorubicin, and cyclophosphamide are each present in a separate pharmaceutically acceptable composition and the compositions are administered sequentially.
40 . The method of claim 37 , wherein the cancer is lung cancer.
41 . The method of claim 37 , wherein the cancer is breast cancer.
42 . The method of claim 37 , wherein the cancer is ovarian cancer.
43 . The method of claim 37 , wherein the cancer is adenocarcinoma.
44 . The method of claim 37 , wherein the cancer is melanoma.
45 . The method of claim 37 , wherein the cancer is leukemia.
46 . The method of claim 37 , wherein the docetaxel, doxorubicin, and cyclophosphamide are each administered parenterally or intraperitoneally.
47 . The method of claim 46 , wherein the docetaxel, doxorubicin, and cyclophosphamide are each administered intravenously.
48 . A method of treating a cancer in a human patient comprising administering an effective amount of a combination of docetaxel, doxorubicin, and cyclophosphamide to the patient, wherein the combination has greater anticancer activity in the human patient than the maximum tolerated dose of docetaxel alone, the maximum tolerated dose of doxorubicin alone, and the maximum tolerated dose of cyclophosphamide alone against said cancer in the human patient.
49 . The method of claim 48 , wherein the docetaxel, doxorubicin, and cyclophosphamide are each present in a separate pharmaceutically acceptable composition and the compositions are administered simultaneously.
50 . The method of claim 48 , wherein the docetaxel, doxorubicin, and cyclophosphamide are each present in a separate pharmaceutically acceptable composition and the compositions are administered sequentially.
51 . The method of claim 48 , wherein the cancer is lung cancer.
52 . The method of claim 48 , wherein the cancer is breast cancer.
53 . The method of claim 48 , wherein the cancer is ovarian cancer.
54 . The method of claim 48 , wherein the cancer is adenocarcinoma.
55 . The method of claim 48 , wherein the cancer is melanoma.
56 . The method of claim 48 , wherein the cancer is leukemia.
57 . The method of claim 48 , wherein the docetaxel, doxorubicin, and cyclophosphamide are each administered parenterally or intraperitoneally.
58 . The method of claim 57 , wherein the docetaxel, doxorubicin, and cyclophosphamide are each administered intravenously.Join the waitlist — get patent alerts
Track US2011263522A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.